^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

Excerpt:
The IFN-γ signature was refined from 10 genes to 6, and the expanded immune signature from 28 genes to 18. Two new signatures enriched in T cell markers and MHC class I and II genes were enumerated based on analysis of top-ranked genes on the platform in melanoma samples: “TCR signaling” (13 genes) and “de novo” (33 genes). All signatures were independently tested in HNSCC and gastric cancer and found to be significantly correlated with clinical benefit...
DOI:
10.1186/2051-1426-3-S2-P80
Trial ID: